Global Erbitux (Colorectal Cancer) - Forecast and Market Analysis to 2023

Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with your industry research requirements or email the details on sales@researchmoz.us

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Erbitux (Colorectal Cancer) - Forecast and Market Analysis to 2023. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems.

To Browse a Full Report with Toc: http://www.researchmoz.us/erbitux-colorectal-cancer-forecast-and-market-analysis-to-2023-report.html

This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

Scope

- Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Erbitux including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Erbitux for the top eight countries from 2013 to 2023.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and...